EGFR and head and neck squamous cell carcinoma: Cetuximab (Erbitux®, Bristol-Myers Squibb; New York, NY), a chimeric monoclonal antibody, which recognizes and binds to the ectodomain of EGFR, preventing its phosphorylation, was one of the first successful drugs in HNSCC [12].